ClinicalTrials.gg
CompletedNCT04770337Updated Apr 8, 2026

Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy

An interventional study of STARSTIM device and Sham Device in Refractory Epilepsy, Focal Seizure and Seizures, Focal, sponsored by Neuroelectrics Corporation. Completed at 32 sites in 4 countries. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Neuroelectrics Corporation · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
127
Allocation
Randomized
Ages
9 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Drug Resistant Epilepsy with a site in United States — 29 open to participants now, 34 under way, 2 of them phase 3. Drug Resistant Epilepsy · United States.

Enrollment
13th of 67
127 · median 27
Started
2021
with 4 others
No phase
38 of 78
22 open now
Registered
39th of 78
by date
Lead sponsor
2 of 78
Neuroelectrics Corporation

Among the 78 studies in Drug Resistant Epilepsy with a site in United States, this one is the 13th largest by enrollment of the 67 interventional ones that give a count, is one of 5 that started in 2021, is one of 38 with no phase, and was the 39th registered.

Drug Resistant Epilepsy

258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.

Browse Drug Resistant Epilepsy studies →

Open to participants now

29 of the 78 studies in Drug Resistant Epilepsy with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Drug Resistant Epilepsy studies recruiting now, 27 (40%) set no upper age limit and 40 (59%) stop at 75 or younger; 27 take children under 18; 6 take healthy volunteers.

This study: 9 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Drug Resistant Epilepsy with a site in United States, or all of them as a file.
02

Study summary

This is a multiple site, randomized, double blinded parallel-group controlled study. The purpose of this study is to evaluate efficacy, safety, and tolerability of repeated, daily sessions with the STARSTIM device, which delivers transcranial cathodal direct current stimulation (tDCS). Subjects will be treated with STARTSTIM or sham device for 10 sessions over a 2-week period. The subjects will be followed for an additional 10 weeks post treatment. Quality of Life questionnaires and adverse events will be collected and evaluated.

Read the detailed description

Study design is an evaluation of the STARSTIM device (tDCS) in subjects over 9 years of age, diagnosed with epilepsy with focal seizures with or without focal to bilateral tonic clonic seizures. Seizure diaries will be collected for 12 weeks to establish a rate of seizure for each subject prior to treatment. Subjects will be randomized in a 1:1 ratio to receive an active STARSTIM treatment or a sham treatment. Neither the study investigator nor subject shall be notified of the treatment assignment. Treatment will be done daily at the investigator's site for 10 days. A Seizure Diary will be maintained through the course of the treatment and the follow up period. Subjects will have 3 follow up visits to evaluate their seizure rate, adverse events, medications and quality of life. A Data Safety Monitoring Board will be utilized to evaluate safety events through study milestones. Seizure frequency rates pre, during and post treatment will be evaluated for both the active and sham treatment arms.

03

Conditions studied

  • Refractory Epilepsy
  • Focal Seizure
  • Seizures, Focal
  • Seizures
  • Epilepsy in Children
  • Epilepsy
  • Epilepsy, Tonic-Clonic

Keywords

  • Epilepsy
  • Focal seizure
  • Seizure
04

Who can participate

Ages eligible
9 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 9 years old or older.
  2. Diagnosis of epilepsy with focal seizures with or without focal to bilateral tonic-clonic seizures (International League Against Epilepsy classification). Diagnosis established by both clinical history and an EEG consistent with focal seizures.

    Note: A normal interictal EEG is consistent with focal seizures, if other data is adequate to provide localization.

  3. Epilepsy is to treatment, defined as: failure to achieve adequate seizure control despite demonstrated compliance, according to medical records, on at least two (2) FDA-approved ASDs at a daily dose considered therapeutic for the patient's demographic according to package labeling, within approximately the last 3 years.
  4. Seizure frequency average of ≥3 per month, over the past year.
  5. Currently on at least 1 ASDs with no changes in antiepileptic drug doses in the 3 weeks prior to baseline visit in the study and no planned dose changes during the trial. Changes after baseline visit are permitted only if clinically necessary.
  6. An MRI scan of the brain using a 1.5 Tesla magnet, or greater, with T1, T2 (recommended), and FLAIR sequences, acquired within the last 3 years for children (patients \<18 years old), or within 5 years for adult patients ≥18 years old, as long as the MRI was obtained after the onset of epilepsy and without brain surgeries after the MRI images.
  7. Seizure focus that allows design of an appropriate stimulation montage. Note: Seizure focus can be identified within a lobe, or 2 adjacent lobes. Identification of the border of the seizure focus can be approximate (+/- 2 gyri).
  8. Available seizure history and supporting data
  9. All female study subjects of childbearing age are required to have a pregnancy test. Additionally, all females of will be required to use an effective method of (defined as having a documented failure rate of \<=1%; for women using enzyme-inducing ASDs hormonal contraceptives will not be considered as effective).
  10. Written obtained from study patient or patient's legal representative and ability for study patient to comply with the requirements of the study.
  11. Assent from pediatric patients when appropriate.

Exclusion criteria

Exclusion Criteria:

  1. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the integrity of the data.
  2. Evidence for more than one seizure focus. (NOTE: For this study, a seizure focus is defined as a cortical region confined to one hemisphere and either one lobe or on a junction of two adjacent lobes from which seizures arise, as documented by scalp or intracranial EEG, that is either supported or not refuted by MRI, and either supported or not refuted by clinical semiology). If the interictal EEG is normal, a seizure focus may be identified by the combination of structural findings on MRI and clinical signs/symptoms associated with the patient's seizures.
  3. Seizure focus is one of: interhemispheric, cingulate, or orbitofrontal
  4. Seizure focus is hemispheric or poorly defined
  5. History of psychogenic non-epileptic seizures in past 2 years, or physiologic nonepileptic seizures and non-epileptogenic events, including suspicion for or a significant history of syncope, and any non-epileptic events must be clearly differentiable from patient's focal seizures based on previously recorded video EEG showing distinct clinical and electrographic features of the patient's psychogenic non-epileptic seizures (PNES) compared to their epileptic seizures.
  6. Seizures of generalized onset
  7. Status epilepticus in the last 12 months
  8. Presence of any disease, medical condition or physical condition that, in the opinion of the Investigator, may compromise interfere, limit, affect or reduce the patient's ability to complete a study duration of 28 weeks (4 weeks screening, 12 weeks baseline, 2 weeks tDCS, 10 weeks follow-up).
  9. Presence of any disease, medical condition or physical condition that, in the opinion of the Investigator, may adversely impact the safety of the patient or the integrity of the data.
  10. Damaged skin on scalp that may interfere with tDCS stimulation.
  11. Pregnant or unwilling to practice during participation in the study.
  12. Nursing mothers.
  13. Any cranial metal implants (excluding ≦1 mm thick epicranial titanium skull plates and dental fillings) or medical devices (i.e., cardiac pacemaker, deep brain stimulator, medication infusion pump, cochlear implant). Note: Vagus nerve stimulator (VNS) is allowable if the device is in MR Mode (e.g., switched off) during tDCS stimulation and the VNS device is MR conditional.
  14. Previous surgeries opening the skull leaving skull defects capable of allowing the insertion of a cylinder with a radius greater or equal to 5 mm.
  15. Substance use disorder (including alcohol) according to Diagnostic and Statistical Manual, 5th edition () criteria in the past 3 years.
  16. Participation in an interventional clinical trial within 30 days prior to screening.
  17. Patient's head circumference > 64 cm
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
127 participants (actual)

Study arms

  • Sham comparator
    Sham treatment

    Subjects will be randomized in a 1:1 ratio to receive an active STARSTIM treatment or a sham treatment.

    Device: Sham Device

  • Experimental
    STARSTIM device treatment

    Subjects will be randomized in a 1:1 ratio to receive an active STARSTIM treatment or a sham treatment.

    Device: STARSTIM device

Interventions

  • DeviceSTARSTIM device

    Cathodal Transcranial Direct Current Stimulation (tDCS). Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered to the brain area of interest via electrodes on the scalp.

  • DeviceSham Device

    Intervention which uses enough currents to generate a sensory feedback similar to that of active stimulation via electrodes on the scalp

06

What researchers measure

Primary outcomes

  1. The difference between active treatment and sham treatment in the percentage change

    Time frame: from baseline in seizures over the 12 weeks following initiation of treatment.

Secondary outcomes

  1. The proportion of subjects who are responders (defined as subjects with a 50% or greater reduction in seizure frequency

    Time frame: from baseline to week 12 post-treatment

07

Study locations

32 sites
  • Barrow Neurological Institute, St. Joseph's Hospital & Medical Center
    Phoenix, Arizona 85013, United States
  • Loma Linda University Health
    Loma Linda, California 92354, United States
  • Keck Medicine of USC
    Los Angeles, California 90033, United States
  • Children's Hospital of Orange County
    Orange, California 92868, United States
  • University of Florida Jacksonville
    Jacksonville, Florida 32209, United States
  • Southern Illinois University School of Medicine
    Springfield, Illinois 62702, United States
  • Sinai Hospital
    Baltimore, Maryland 21215, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • Boston Children's Hospital Comprehensive Epilepsy Center
    Boston, Massachusetts 02115, United States
  • Beth Israel Deconess Medical Center
    Boston, Massachusetts 02215, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University Medical Center
    St Louis, Missouri 63110, United States
  • Robert Wood Johnson Medical School (Rutgers)
    New Brunswick, New Jersey 08901, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • University of Pennsylvania (Penn Epilepsy)
    Philadelphia, Pennsylvania 19104, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37212, United States
  • University Of Utah
    Salt Lake City, Utah 84132, United States
  • Seattle Children's Hospital, University of Washington
    Seattle, Washington 98105, United States
  • Cliniques Universitaires Saint Luc
    Brussels, Belgium
  • Ghent University Hospital
    Ghent, Belgium
  • Hospices Civils De Lyon
    Lyon, France
  • CHU de Marseille - Hôpital de la Timone
    Marseille, France
  • Hospital Universitario Albacete
    Albacete, Spain
  • HM Nou Delfos
    Barcelona, Spain
  • Hospital Clínic
    Barcelona, Spain
  • Hospital Del Mar
    Barcelona, Spain
  • Hospital Sant Joan de Déu
    Barcelona, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, Spain
  • Hospital Niño Jesús
    Madrid, Spain
  • Hospital Ruber Internacional
    Madrid, Spain
  • Hospital Universitario Regional de Málaga
    Málaga, Spain
  • Centro de Neurología Avanzada
    Seville, Spain
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Jan 2026, 50 months.

Of 102 interventional studies with no phase under Drug Resistant Epilepsy, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 50. This study's 50 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2021
First posted
Feb 25, 2021
StartActual
Oct 25, 2021
Primary completionActual
Jan 12, 2026
CompletionActual
Jan 12, 2026
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04770337
Lead sponsor
Neuroelectrics Corporation
Responsible party
Sponsor
First posted
Feb 25, 2021
Start date
Oct 25, 2021
Primary completion
Jan 12, 2026
Completion
Jan 12, 2026
Last update
Apr 8, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion